COMPETITIVE TECHNOLOGY BENCHMARKING / EXAMPLE ENGAGEMENT
Continuous manufacture of sterile injectable products
An anonymised scenario showing how a biopharma team could assess whether peer activity is building a credible manufacturing capability that may affect future partner or platform choices.
PROCESS DESIGN
QUALITY SYSTEM
FACILITY SIGNALS
READINESS
The decision scenario
A biopharma team is preparing a multi-product sterile injectable pipeline and expects future pressure on supply resilience, changeover flexibility, process control and scale-up transfer. Several CDMOs, equipment providers and adjacent manufacturers have started to discuss continuous manufacturing, advanced control or integrated aseptic operations. The client does not need an exhaustive market view. It needs to know whether selected peer activity signals a practical capability that could change its future outsourcing or technology-platform options.
THE QUESTION Are peer groups assembling the linked process, control, quality and facility capabilities needed for continuous manufacture, or are the visible signals still limited to technical positioning?
Why this question matters
ICH Q13 describes scientific and regulatory considerations for the development, implementation, operation and lifecycle management of continuous manufacturing for drug substances and drug products, including chemical entities and therapeutic proteins. That makes a credible competitor signal more demanding than a pilot announcement: the team must understand whether process technology is being linked to a control strategy, quality system, facility design and a suitable product route.
Potential blind spot | Potential overreaction |
|---|---|
A peer may be creating a differentiated partner position by combining equipment, process analytics, automation and quality-system readiness before publicly naming customer programmes. | A continuous manufacturing announcement may be read as sterile-injectable readiness even when the published scope relates to a different dosage form, product stage or operating model. |
A capability may be relevant for selected products, not for every sterile injectable programme. | Regulatory guidance can be mistaken for a proof of operational execution or an assurance of approval. |
Factual context: FDA and EMA describe ICH Q13 as addressing development, implementation, operation and lifecycle management of continuous manufacturing for drug substances and drug products. Source: FDA and EMA, ICH Q13 guidance, accessed August 2026.
COMPETITIVE TECHNOLOGY BENCHMARKING / CAPABILITY STAIRCASE
How the benchmark is executed
Capability step | Public evidence reviewed | Interpretation question |
|---|---|---|
1. Process route | Technical papers, product literature, equipment references and relevant patents. | Is there evidence of a defined continuous process route rather than a broad automation claim? |
2. Control strategy | PAT, automation, process-model and data-integrity disclosures. | Is process control linked to the critical quality and operational decisions required for the stated scope? |
3. Quality and regulatory readiness | Quality-system material, public guidance engagement, facility and submission references. | Is the operating model being designed with lifecycle management and regulated manufacture in mind? |
4. Facility and partner route | Facility announcements, equipment partnerships, hiring and CDMO service materials. | Is there visible operational commitment and a route to serve the relevant client type? |
5. Translation evidence | Product-stage references, customer collaborations and repeated programme signals. | Is there any corroborated indication that the capability is moving beyond internal or promotional activity? |
Hypothetical capability staircase
PROCESS ROUTE
CONTROL
QUALITY
FACILITY
TRANSLATION
Peer group | Illustrative highest visible step | Hypothetical interpretation | Decision lane |
|---|---|---|---|
A | Facility and partner route, with linked process-control and quality evidence. | The peer may be assembling a credible option for targeted programmes; product-specific fit remains unproven. | Investigate |
B | Control strategy, with technical and equipment signals but no visible facility or service route. | Technology development appears stronger than operational translation. | Monitor |
C | Process-route messaging only. | Insufficient evidence of quality-system or commercial readiness. | Deprioritise |
COMPETITIVE TECHNOLOGY BENCHMARKING / ANSWER FORMAT
What a useful answer could look like
The answer would not declare any peer “ready” for continuous sterile injectable manufacture. A bounded hypothetical conclusion could identify one peer group whose public evidence spans the process, control and operating-model layers well enough to justify targeted partner due diligence. The team could then decide whether to ask more precise questions about product fit, aseptic boundary, quality strategy and transferability.
FOCUS PARTNER SCREEN
DEFINE PRODUCT FIT
REFRESH ON NEW EVIDENCE
Delivery and website presentation
A focused benchmark could take approximately three to five weeks. Present the website example as an ascending capability staircase. Each step opens a short card explaining what public evidence can support and what it cannot establish. Use an expandable vertical staircase on mobile.
NOTE This is a hypothetical website scenario, not a finding about a named manufacturer. Peer labels, evidence patterns, readiness steps and actions are illustrative and cannot replace GMP, regulatory or technical assessment.
Let’s discuss your competitive question
August Research can design a bounded, evidence-led benchmark that clarifies which signals deserve attention, which remain uncertain and what should trigger the next decision.